Atazanavir
- Generic Name
- Atazanavir
- Brand Names
- Evotaz, Reyataz, Atazanavir Krka, Atazanavir Viatris (previously Atazanavir Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C38H52N6O7
- CAS Number
- 198904-31-3
- Unique Ingredient Identifier
- QZU4H47A3S
- Background
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the pa...
- Indication
Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with cobicistat and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at l...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 1125
- Registration Number
- NCT00013520
- Locations
- 🇺🇸
The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Northwestern University CRS, Chicago, Illinois, United States
🇺🇸St. Louis ConnectCare, Infectious Diseases Clinic, St. Louis, Missouri, United States
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002240
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Albany Med College, Albany, New York, United States
🇺🇸Clinsites / Sorra Research Ctr, Birmingham, Alabama, United States
Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 55
- Registration Number
- NCT00007202
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Inc. (ARCA) AIEDRP CRS, Atlanta, Georgia, United States
🇺🇸Feinberg School of Medicine, HIV/ACTU AIEDRP CRS, Chicago, Illinois, United States
🇺🇸Rush Univ. Med. Ctr., Dept. of Infectious Disease AIEDRP CRS, Chicago, Illinois, United States
A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00013897
- Locations
- 🇺🇸
Associates in Research, Fort Myers, Florida, United States
🇺🇸The CORE Ctr, Chicago, Illinois, United States
🇺🇸Ohio State Univ Hosp, Columbus, Ohio, United States
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00004584
- Locations
- 🇺🇸
HIV Clinical Research, Fort Lauderdale, Florida, United States
🇺🇸Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States
🇺🇸Albany Med College, Albany, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.